You are here

Neupro Launched in U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome

The effectiveness of rotigotine in the treatment of the signs and symptoms of idiopathic PD was established in five parallel-group, randomized, double-blind, placebo-controlled trials conducted in the U.S. and abroad. Depending on the trial design, PD patients underwent a weekly titration of rotigotine in 2 mg/24 hrs increments to either the randomized dose or the optimal dose.

The efficacy of rotigotine in the treatment of RLS was primarily evaluated in two fixed-dose, randomized, double-blind, placebo-controlled trials with 6-month maintenance periods. Patients received rotigotine dosages ranging from 0.5 mg/24 hrs to 3 mg/24 hrs or placebo once daily.

In clinical trials, the most common adverse reactions for the highest recommended doses of Neupro for the treatment of PD were nausea, vomiting, somnolence, application-site reactions, dizziness, anorexia, hyperhidrosis, insomnia, peripheral edema, and dyskinesia. The most common adverse reactions for the highest recommended dose of Neupro for the treatment of RLS were application-site reactions, nausea, somnolence, and headache.

Read the news story from the Sacramento Bee.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function